Charles River is pleased to announce our collaboration agreement, which grants us commercial access to the high-throughput screening (HTS) and compound management infrastructure of AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. Through this new agreement, we will perform HTS programs for our clients utilizing AstraZeneca’s state-of-the-art HTS facility.
Charles River will place scientists-in-residence at AstraZeneca’s Centre for Lead Discovery in Cambridge, United Kingdom, to manage our compound collections and run drug discovery screens for clients with a comprehensive range of assay technologies, liquid handling platforms, and automated storage systems. The highly dynamic and brand-new compound management and HTS facility is equipped with state-of-the-art technologies like acoustic mass spectrometry to provide efficient drug discovery screening services from assay conception to hit identification.
Ian Waddell, Ph.D., Executive Director, Biology at Charles River, said, “Providing our clients access to AstraZeneca’s HTS technology enhances our existing capabilities by broadening our assay platforms and increasing our ability to automate, ultimately allowing us to execute HTS projects with greater speed and accuracy.”
Using our compound screening libraries and advanced screening platform technologies can help you identify and validate hit compounds. We can also provide compound screening services for client libraries with a capacity of up to 1 million compounds in single compound format or up to 3 million in compressed formats, with the ability to store a copy of your library for multiple screening campaigns.